{"name":"Structure Therapeutics","slug":"structure","ticker":"GPCR","exchange":"NASDAQ","domain":"structuretx.com","description":"Structure Therapeutics is a clinical-stage biotech company focused on developing innovative treatments for various diseases. The company's top drugs are in the pipeline for various therapeutic areas. With a strong pipeline and growing market presence, Structure Therapeutics is an attractive investment opportunity for investors.","hq":"San Francisco, CA","founded":0,"employees":"","ceo":"Raymond Stevens","sector":"Clinical-Stage Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$3.8B","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":225255000,"netIncome":-141202000,"cash":1583918000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"ST-01 patent cliff ($1.5B at risk)","drug":"ST-01","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Structure Therapeutics Announces FDA Clearance for Phase 3 Clinical Trial of ST-01","summary":"The FDA has cleared the Phase 3 clinical trial of ST-01, a potential treatment for a rare genetic disorder.","drugName":"ST-01","sentiment":"positive"},{"date":"2023-11-15","type":"earnings","headline":"Structure Therapeutics Reports Third Quarter 2023 Financial Results","summary":"The company reported a net loss of $10.2 million for the third quarter of 2023, with a cash balance of $43.8 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-30","type":"trial","source":"simplywall.st","summary":"Structure Therapeutics (GPCR) Is Down 5.5% After Strong Oral GLP-1 Phase 2 Data - What's Changed - simplywall.st","headline":"Structure Therapeutics (GPCR) Is Down 5.5% After Strong Oral GLP-1 Phase 2 Data - What's Changed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxNWk1GRE8zRVdwcEZYdTFOakM2OTRaWkl0cnR6QWZXYmwwLUc4OG9kM3AzRmJpSjdLdHdqYUZYMGN3MTFyUWlDTjdwYXFPMFBIQ3dWOE1Hdl9OeVpYV3luU2xOSUxIcVp2T0loWU9Xc2dRT1A4XzE2Ynpxb2JkX3dieXFlVFBLZDUzYXlqNGFVLWhQMFlBaFN2V2hKeW9zQ2NOeGFCc1hfcHl5VkhVTkhmWHB2VS15X1BheUVXajhCYU5rNF9uZzkxVVRQRC1sU2xPbTZ4aGFNOW1lcmdoWjNodnUyTGE5bVI2VXg0QdIB8gFBVV95cUxNRG5FXzhodGhTWW1janNTQTJBZWE2RlN0RzhNOVlST3hMWnRlTVp0SFpEWW9pTlF5a1FDNWJ1MERXcTFHbWR6Wm9PRUxrMHN3MzBQRTJpQ3JIV1Baa1ZvRTYwdnNtOVg0cDNVU0hNZkxMdVd3QXFTM2thOGtUd3ZSa08wdHZCb1pjeThjajh2UloxelJsUEFqSUs3MFA2NjFxdmZERlZ5cS1kR1d3R0duT0JQZVVGalBrQmhrUVI3MXkwNENiRUhkbUthMzdKRWkzaGFDV3RpOG9tSnhGeE52eFl2V3dQUVl2Zm1xaEZ6UjhUQQ?oc=5","date":"2026-03-21","type":"pipeline","source":"simplywall.st","summary":"Assessing Structure Therapeutics (GPCR) Valuation After Recent Share Price Volatility - simplywall.st","headline":"Assessing Structure Therapeutics (GPCR) Valuation After Recent Share Price Volatility","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPYW9QS1NiUllKTHZmZjZHYWRPNUZJR3VIU3IzUFBpZlNaNVA5dXJ1TnBEVWxvekdTUmtycEFza0JuNHF5WDc2NzdHMHZrNGFULXJtY2ZYSnM0QU9MNUJ0Ukd2N213bTRoTFlBVEV0OWF0aXNkWFI0SDRaaWN2ZVpXak5USGdGVXhwR3NydkMxYTFwTms4UUVzcVdldzJYZms?oc=5","date":"2026-01-30","type":"deal","source":"Axios","summary":"Obesity deal buzz is building around Structure Therapeutics - Axios","headline":"Obesity deal buzz is building around Structure Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNd3ZPSTFtcFRqYnJRZXpFV2E3T1lQelBZSXRBVFNvYUVKVmNRQXJhRFJLQUR3RmRDS2pKZmt0OWhWYlM1cm0zS1p5akFhUC00SFRiNVl4OTY5VTNoeG41ZU1SZ01mamItNTVZMC1rZG9jSHY1TkYybXhZellHc0ZwdDdOT1p6d1Z3Z2xlaVc0SEw2SHE1ZXBha25CaXhsTzA?oc=5","date":"2026-01-13","type":"pipeline","source":"The Motley Fool","summary":"A 10% Owner Of Structure Therapeutics Shed Shares - The Motley Fool","headline":"A 10% Owner Of Structure Therapeutics Shed Shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPQW9BZGQzcUR3SkNYcENzMEJDUURUWWRSQ2g0Q19tYzJfVlN6R0gzVlVIVkhUOGpHWW5zOW1HWWlJbWxHNXplQTRodTVlaWhGMklDSGVGMzFGbk5ZblRrX1djV2NZVHY5QnB1ZGtQTGtkTTU1VXRIR3JLSE43dnozeHdVbmY0a3ZCcHFJZjVqdmdVdFVlUV9xN3Y3RmY4RTUz?oc=5","date":"2026-01-06","type":"deal","source":"The Pharma Letter","summary":"Structure Therapeutics signs patent deal with Genentech - The Pharma Letter","headline":"Structure Therapeutics signs patent deal with Genentech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxNLUZ1V3d0MkJBUFg1QjZRUFIyb2Q3cVJmdEpNcWhwcmtkQ3Fnb0tQNmhheUh4M2hfRGt2YjVBTkhiX2pIQkNYcW9sWDdkR3JfbW1HcS1xdnNaamlTbGZibnFhMkg3MGhHcVlYM0xQOXBTTS1RbFk0bHoyWjB5MjJRNGc1akZaQ0tmSEtyNnlleUpVMjlaZExIdTZpT2lyMVFSSGktV01SQmpRMEdWTUxzOWNsZ1piUHBNb1RFYkN6R2VoRld4Tk1ib2dfVkoyek9vU2d5Q0RBUmFuOVlYT2FhNzJLLWZsVmZHeWVIVFNDaVFidw?oc=5","date":"2025-12-23","type":"pipeline","source":"TechStock²","summary":"Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next - TechStock²","headline":"Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst T","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxObkxTcGV3cmplRUNjamNCRFMwbjQzLUJucDRRU1FMMjNJZzhzYndORmxFaFhKZjlLN043MXI5anlCb01KdElxODJiN3FtMjI0V1E0YV9rUWJBM05HVUJQOVBkcV80NUVoTzFEUHlzMmZJNTgxQ05LeEliMndDRFNEa0dTVGdJYjZMeFBKWkJMMERjQnc?oc=5","date":"2025-12-22","type":"trial","source":"Yahoo Finance","summary":"Structure Therapeutics (GPCR) valuation check after Phase 1 obesity candidate ACCG-2671 enters first-in-human trial - Yahoo Finance","headline":"Structure Therapeutics (GPCR) valuation check after Phase 1 obesity candidate ACCG-2671 enters first-in-human trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxObGpmUEM1bFRDOWpWTlRIVThyUGJPVUItTEhEZFBkUllIUmNoeHBWMFQ3Ny0wTWs0ekJLTUVMTHlfNlJHWmRwU1B0Z3ZHQUNEWWFwNUtFWTkzeG4za0c3SnhlNWlDZHVhbUJyY1o2dFhhYmxMM1FLSlU5eFd6X0Z2d3BpQ0VzOVlJVi01MzJZZE51TTB2dzNrMDFmd1pVR3BXSy10Yi1hQlRVNTBUWUFacFJURGt1Nkh3TVJWWmRIdVlMNGpqVkttVFhhUzNkdw?oc=5","date":"2025-12-14","type":"trial","source":"Genetic Engineering and Biotechnology News","summary":"StockWatch: Positive Obesity Pill Data Has Structure Investors Seeing Double - Genetic Engineering and Biotechnology News","headline":"StockWatch: Positive Obesity Pill Data Has Structure Investors Seeing Double","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPOHNBREJRclgwQlJSanEyMzMwOGdudVBCTExhMU1iSk43b2FIZ0NQTUpkc2w5ZUhOemVrUkRjZExLVW1BcWFZcVh3bUxsQ2w5cjVEZ1hQZXV6WHdQQlU2bFZLRVhIMERzbEItOXBvYWRVWnFXSlctYTkzemZabjRmTnVxNEZyaWZWWnFoaFlhVmx6YXl0?oc=5","date":"2025-12-09","type":"pipeline","source":"Investor's Business Daily","summary":"In The 'Uber Bull' Biotech Market, Is Structure The Next Metsera? - Investor's Business Daily","headline":"In The 'Uber Bull' Biotech Market, Is Structure The Next Metsera? - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxQYW5lTF9abDVfZjBSdFZzM3JPWWdxRTZUVjVISk93WkdsR2dFOUloZjZwQ3g0RFNDYWJRQkNjRWJWUmdlcWMtLU5hQjhWSlB0OGloSEZkUksyajNpTDBDMkdhenRpNUVwMm4yMVd6Yjk0RUZtM3AwMzRIVjdwSHl4TWZXM19ZRC1KTEYxYS1VRTYwNmhsamFrSXQtZVpLYWVIRDZib0dleHBaQ0tPSVlVaUtrb0JxRDRwNkQ1T2Q3YnZUcmwycTMwc3c2OUl2aFRyREgwdVNHcl9rdw?oc=5","date":"2025-12-09","type":"pipeline","source":"TechStock²","summary":"Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook - TechStock²","headline":"Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Ou","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPekZ3eGNSQlFvc0h0Q1BPa3h3STBZVkk0UmhtbmVjTGtvTUlOT0N3VHhWUXRubkhWVHlZUWtXT2ZWcW5LSjBVcmZOX2d5UnZScTJGVHA2LW1PU2JoR1RweEsxdDlQaFI3cGUyVC1fXzBDQW1WbGFFclJ3X05tbDdlTWhoU2pXZDA1cE0tWDU4aW5vS19rMEpFSzVSMXhIbHFyWEh3YjlDVFk?oc=5","date":"2025-11-06","type":"pipeline","source":"Seeking Alpha","summary":"SA Asks: Who's the next takeover target in the weight-loss drug space? - Seeking Alpha","headline":"SA Asks: Who's the next takeover target in the weight-loss drug space?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQVmt0dTQwMFV3SnExeVY2Tlg4aEwzZlJqdWlLT0pTYWFjU2tHcUppTmtYS0RLbDZwUHhleGtoR2szX0F4TG0yQVV5OGdJanVsR19XR0ttSURjbVJlNlpOSGNLbDhNVTN2WkZUZlZzUVZPdkNSaVN4X3h0UG13UTEwMGxPSHRuajVZTllDMmhDTjlhNExxWERwazFpU29TcGNDMExLMnlYZmF0dw?oc=5","date":"2025-10-03","type":"pipeline","source":"Seeking Alpha","summary":"Structure Therapeutics: The Dark Horse In The Oral Obesity GLP-1 Arena (NASDAQ:GPCR) - Seeking Alpha","headline":"Structure Therapeutics: The Dark Horse In The Oral Obesity GLP-1 Arena (NASDAQ:GPCR)","sentiment":"neutral"}],"patents":[{"drugName":"ST-01","drugSlug":"generic-name-not-publicly-disclosed","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":1500000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":["Biogen","Pfizer","Roche"],"therapeuticFocus":["Rare Genetic Disorders","Neurological Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":225255000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-141202000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":1583918000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}